A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers shows that a monoclonal antibody therapy called MAR001 can significantly reduce triglyceride levels within 12 weeks for patients with high triglyceride levels. Their results are published in the New England Journal of Medicine and were presented simultaneously at the American Heart Association’s annual meeting.
“Despite advances in lipid-lowering therapy, many patients continue to have elevated triglyceride levels and cardiovascular risk,” says lead author Michelle O’Donoghue, a cardiologist with the Mass General Brigham Heart and Vascular Institute and senior investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group. “Our findings suggest that MAR001 may be able to safely and effectively lower triglycerides.”
Several classes of drugs have been previously shown to lower triglycerides, but MAR001 is novel because it targets ANGPTL4, a protein that naturally inhibits lipoprotein lipase, an enzyme that breaks down triglycerides.









